Business Wire

ASI

27.3.2024 14:01:34 CET | Business Wire | Press release

Share
Fetch.ai, Ocean Protocol and SingularityNET Unite to Create Artificial Superintelligence Alliance

SingularityNET (SNET), the world's first decentralized Artificial Intelligence (AI) network, Fetch.ai, a Web3 platform for the new AI economy, and Ocean Protocol, a decentralized data exchange platform to protect data, today announced the launch of the Artificial Superintelligence Alliance. The creation of the largest open-sourced, decentralized network through a multi-billion token merger is a major step that accelerates the race to Artificial General Intelligence (AGI).

The Alliance is the brainchild of three leading minds in decentralized AI. Dr. Ben Goertzel, renowned as the “Father of AGI”, founded SNET as a blockchain-based marketplace and framework for AI services. DeepMind founding investor Humayun Sheikh built Fetch.ai as a decentralized multi-agent platform to deploy and commercialize AI applications. Trent McConaghy, the architect of the AI-based software that most chip designers use to drive Moore’s Law, formed Ocean Protocol to provide a platform for data exchange and the seamless trade of tokenized data assets.

As part of the formation of the Alliance, the $FET, $OCEAN and $AGIX tokens that fuel the three Alliance member networks will be merged into a single $ASI token that will function across the combined decentralized AI network, providing unprecedented scale and power.

Built for Super Intelligence

“As the AI revolution intensifies it is imperative that AGI and ASI are not owned and controlled by any particular party with their own biased interests,” comments Dr. Ben Goertzel, CEO and Founder of SNET. “They should be rolled out in an open, democratic and decentralized way. This has been the joint vision of SNET, Fetch.ai and Ocean Protocol from their inception, and for this reason it makes total sense that our three projects come together to form a tokenomic network that has greater power to take on Big Tech and shift the center of gravity of the AI world into the decentralized ecosystem.”

“In a world of exponential AI innovation, the giants of Big Tech dominate the headlines and conversation,’” remarks Humayun Sheikh, Fetch.ai CEO & Founder. “We are forging a different path. Our mission with this token merger is to combine our platforms to ensure ethical and transparent AI that facilitates direct interactions between developers and users to bypass the traditional gatekeepers of centralized authorities. This enhances data privacy and paves the way for a more democratic and trustworthy AI ecosystem and encourages global participants to contribute.”

Compelling Strategic Rationale

  • Catalyzed by Rise of AI and Growth of Three AI Projects: The combination is born of a period of unprecedented growth for the AI projects. The deal provides an unparalleled opportunity for these three influential leaders to create a powerful compelling alternative to Big Tech’s control over AI development, use and monetization.
  • Creates a Decentralized AI Infrastructure at Scale: Decentralized AI leverages blockchain technology to turn AI systems, whose inner workings are hidden from the public, into open networks for coordinating machine intelligence towards shared objectives. The fusion of SNET, Fetch.ai and Ocean Protocol’s research, brands, technologies and products creates a foundation to build a scalable AI infrastructure which ensures ethical and trustworthy practices.
  • Accelerates Investment into AGI: Goertzel, Sheikh and McConaghy have long been acolytes and early-adopters of Artificial Intelligence – all focused on making AGI a reality. This Superintelligence Alliance facilitates the commercialization of each foundation’s technology, and enables wide scale access to cutting-edge AI platforms and large databases. This groundbreaking move advances the path to AGI on the blockchain.

Transaction Details

Bruce Pon, Ocean Protocol CEO & Co-Founder, believes the combination can deliver on the promise of a vertically integrated stack of decentralized technologies with scale to compete globally. “The combination of our technologies creates a leader in R&D, applications and commercialization of AGI,” Pon notes. “The unified $ASI token is the glue to orchestrate all actors with common incentives. $ASI tokens are used to secure the public network, as data access tokens and to unlock computation without needing traditional banking and payment rails. It is the native currency for the machine economy.”

If the proposal receives majority approval from the respective communities, the following will occur:

- $FET will be rebranded as $ASI, with a total supply of 2.63055 billion tokens
- $AGIX tokens migrate to $ASI, at a conversion rate of 0.433350:1
- $OCEAN tokens migrate to $ASI, at a conversion rate of 0.433226:1
- If the FDV of all three tokens as of March 26, 2024 were carried over fully into $ASI, it would have a total combined FDV of $7.6 billion USD.

Leadership and Governance

Upon closing of this token merger, a governing council for the Artificial Superintelligence Alliance will form to monitor and guide operations of the newly merged tokenomic network. The Alliance will be led by Ben Goertzel, Humayun Sheikh, Bruce Pon and Trent McConaghy. The organizations that guide development of the three merging networks, Fetch.ai, Ocean Protocol Foundation and SNET Foundation, will continue to operate as separate entities, but will collaborate closely in the shared $ASI tokenomic ecosystem and in the operation of the Alliance.

“Among our many commercial and research goals for this combined network to work is to launch a decentralized neural-symbolic AGI system with globally-superior capabilities in key areas like logical and scientific reasoning and artistic creativity,” Goertzel continues. “The impact of such a system may greatly exceed what we’ve seen from significant LLMs and lead the global economy into a new era of beneficial decentralized AGI and ASI.”

About SingularityNET

SingularityNET was founded by Dr. Ben Goertzel with the mission of creating a decentralized, democratic, inclusive and beneficial Artificial General Intelligence (AGI). According to Dr. Goertzel, AGI should be independent of any central entity, open to anyone and not restricted to the narrow goals of a single corporation or even a single country. The SNET team includes seasoned engineers, scientists, researchers, entrepreneurs, and marketers. The core platform and AI teams are further complemented by specialized teams devoted to application areas such as finance, robotics, biomedical AI, media, arts and entertainment.

For additional information on SNET, visit: https://singularitynet.io/

About Fetch.ai

Fetch.ai, a Cambridge-based AI company, is redefining the possibilities of an intelligent and connected world through its AI agent-based technology. Fetch.ai's infrastructure technology enables developers and businesses to build, deploy & monetize through an agent-based modular platform for the new generation of AI applications. The company's core product, DeltaV, fuses Language Models (LLMs) and AI Agents to create an open and dynamic marketplace that connects users to services and reimagines the current search experience.

Learn more at www.fetch.ai and on X.

About Ocean Protocol

Ocean was founded to level the playing field for AI and data. Ocean tools enable businesses and individuals to trade tokenized data assets seamlessly to manage data all along the AI model life cycle. Ocean-powered apps include enterprise-grade data exchanges, data science competitions and data DAOs. The Ocean Predictoor product has over $800M in monthly volume six months after launch with a roadmap to scale foundation models globally.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240327003765/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye